TherapeuticsMD (TXMD) EBT Margin (2011 - 2026)
TherapeuticsMD's (TXMD) quarterly EBT Margin came in at 18.87% in Q2 2026, down 3838.0% on a YoY basis from 0.5% in Q2 2025, and up 32.66% quarter-over-quarter from 14.23% in Q1 2026.
Powered by 
Analysis
TherapeuticsMD (TXMD) EBT Margin (2011 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has reported EBT Margin for 16 consecutive years, with 18.87% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 3838.0% year-over-year to 18.87%; the trailing twelve-month figure through Jun 2026 stood at 8.04% (up 1568.0% YoY), and the FY2025 full-year result was 21.61%, up 11144.0% from the prior year.
- EBT Margin improved to 18.87% in Q2 2026 per TXMD's latest filing, from 14.23% in the prior quarter.
- Across five years, EBT Margin topped out at 70.67% in Q4 2022 and bottomed at 4273.85% in Q2 2022.
- Historically, EBT Margin has averaged 887.43% across 5 years, with a median of 214.22% in 2024.
- The sharpest annual moves came in 2022 and 2023: EBT Margin sank 408842 bps in 2022, then soared 372145 bps in 2023.
- Over 5 years, EBT Margin stood at 70.67% in 2022, then tumbled by 547 bps to 315.54% in 2023, then surged by 104 bps to 12.44% in 2024, then tumbled by 622 bps to 64.95% in 2025, then soared by 129 bps to 18.87% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 18.87%, 14.23%, and 64.95% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 29.63% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -4.34% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 31.50% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 12.17% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 18.33% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 18.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.87% |
| Mar 31, 2026 | 14.23% |
| Dec 31, 2025 | -64.95% |
| Sep 30, 2025 | 6.38% |
| Jun 30, 2025 | 57.25% |
| Mar 31, 2025 | -169.97% |
| Dec 31, 2024 | 12.44% |
| Sep 30, 2024 | -103.66% |
| Jun 30, 2024 | -448.72% |
| Mar 31, 2024 | -258.47% |
| Dec 31, 2023 | -315.54% |
| Sep 30, 2023 | -2,705.66% |
| Jun 30, 2023 | -552.40% |
| Mar 31, 2023 | -555.29% |
| Dec 31, 2022 | 70.67% |
| Sep 30, 2022 | -4,133.05% |
| Jun 30, 2022 | -4,273.85% |
| Mar 31, 2022 | -2,571.94% |
| Dec 31, 2021 | 268.50% |
| Sep 30, 2021 | -186.65% |